Article Figures & Data
Figures
- Fig. 1.
Effect of Apo2L on growth of glioma cell lines. The relationship between Apo2L concentration and cell numbers, as assessed by a spectrophotometric measurement of MTS bioreduction, is illustrated in the U87, A172, T98G, and LN-Z308 malignant glioma cell lines. Points represent the mean of three measurements; bars, ± SD. Y axes vary between cell lines to illustrate the response range observed. No significant inhibition was detected in control cells treated with the concentration of vehicle used at the highest Apo2L/TRAIL dose level; control values are indicated as ▪ on the right border of each graph. All of the results were confirmed in a second, independent experiment.
- Fig. 2.
Effect of Apo2L on growth of a non-neoplastic astrocyte cell line. The relationship between Apo2L concentration and cell numbers is assessed as in Fig. 1<$REFLINK> . Values in control cells treated with the concentration of vehicle used at the highest Apo2L/TRAIL dose level are indicated on the right border of the graph.
- Fig. 3.
Effect of Apo2L on clonogenic growth of glioma cell lines. The relationship between colony counts and Apo2L concentration in the U87, T98G, and LN-Z308 cell lines is shown. Cells were treated with Apo2L for 6 and 96 h and then grown for an additional 14 days in the absence of the ligand. Colonies were then counted. These results were confirmed in a second, independent experiment.
- Fig. 4.
Time course of apoptosis induction by Apo2L (A). Apoptotic percentage, assessed by terminal transferase-catalyzed end labeling of DNA fragments, after various intervals of exposure to 300 ng/ml of Apo2L in U87 malignant glioma cells and N49 non-neoplastic astrocyte cells is shown. Whereas the apoptotic labeling percentage reached 30% in U87 glioma cells after 24 h of exposure to Apo2L/TRAIL and remained elevated (96-h result is illustrated in B), the labeling percentage remained less than 3% in non-neoplastic astrocytes, even after extended intervals of Apo2L treatment, as well as in vehicle-treated control glioma cells (96-h result is shown in C).
- Fig. 5.
Effect of caspase inhibitors on the activity of Apo2L. After pretreatment with Ac-YVAD-CMK or Ac-DEVD-CHO, U87 and LN-Z308 glioma cells were treated with Apo2L, and cell numbers were assessed as in Fig. 1<$REFLINK> .
- Fig. 6.
Effect of Apo2L on survival of nude mice after intracranial implantation of U87 glioma cells. Kaplan-Meier survival curves for control animals and those treated with various concentrations of Apo2L are shown. Differences between control and each of the Apo2L-treated groups were statistically significant (P < 0.001) as were the differences between the survival of animals in the 30 mg/kg/day-group and those receiving lower doses.
Volume 7, Issue 5
